Polaris Pharmaceutical

Advancing A Clinical Stage Pipeline For Multiple Cancers

About this Event

Polaris Pharmaceuticals is a global, vertically integrated, biopharmaceutical company on a mission to transform the treatment of cancer and metabolic disease through innovative biologic therapies.

At the center of their pipeline is Pegargiminase (ADI‑PEG 20) a biologic with the potential to treat several cancers. Polaris has successfully completed a Phase 3 trial for malignant pleural mesothelioma, with the FDA review expected to be complete in June of 2026.

ADI-PEG 20 is also in clinical trials for glioblastoma, soft tissue sarcoma, hepatocellular carcinoma, and acute myeloid leukemia. Each is a devastating cancer affecting hundreds of thousands of people every year.

Register today to watch our online event with the leaders from Polaris to hear more about their innovative pipeline the company projects will provide long-term revenues exceeding $2–3 billion annually.

Video On Demand

– Recorded

January 7

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.